Clinical comprehensive evaluation of [(18)F]AlF-FAP-NUR PET: multi-time-point imaging, head-to-head comparison with [(18)F]FDG.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethical approval: This study was performed in line with the principles of the Declaration of Helsinki. The clinical translational study was approved by the institutional review board of the First Affiliated Hospital of Guangzhou Medical University (ES-2023-083-01), and written informed consent was obtained from the patient before the study. Consent for publication: The authors affirm that human research participants provided informed consent for the publication of all the images. Competing interests: The authors have no relevant financial or non-financial interests to disclose. 12. Bosn J Basic Med Sci. 2018 Feb 20;18(1):72-79. doi: 10.17305/bjbms.2017.2179. The value of 18F-FDG PET/CT imaging in breast cancer staging. Yararbas U(1), Avci NC, Yeniay L, Argon AM. Author information: (1)Department of Nuclear Medicine, Ege University Medical Faculty, Izmir, Turkey. ulkemyararbas@gmail.com. The National Comprehensive Cancer Network (NCCN) guidelines recommend assessment with positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) in staging of breast cancer, starting from the stage IIIA. Previously, PET/CT contributed to the accurate staging from the stage IIB. Our aim is to evaluate the contribution of 18F-FDG PET/CT in staging of breast cancer patients. A total of 234 patients were retrospectively evaluated. PET/CT was performed preoperatively in 114/234 and postoperatively in 120/234 patients. Initial staging was performed based on histopathological results in 125/234 and clinical results in 109/234 patients, according to the American Joint Committee on Cancer (AJCC) classification. All patients had a normal abdominal ultrasound and chest x-ray. Following PET/CT imaging, modification in the staging was performed in patients with the metastatic findings. In 42/234 (17.9%) patients hypermetabolic extra-axillary regional lymph nodes and in 65/234 patients (27.7%) distant metastatic involvement were detected with PET/CT. Modification in the staging was applied in 82/234 (35%) patients. Patient management was changed in 69/234 (29.4%) cases. The percentage of patients with upstaging, according to each stage, was as follows: IIA: 18.6%, IIB: 30%, IIIA: 46.3%, IIIB: 68.8%, and IIIC: 20.8%. In 43/43 patients, 99mTc-methylene diphosphonate (MDP) bone scan did not show additional bone metastasis. In 5/32 patients, metastatic involvement was detected with sentinel lymph node biopsy (SLNB), but preoperative PET/CT scan did not reveal hypermetabolic lymph nodes. Although our study was limited by the referral bias and lack of homogeneity in the referral group, PET/CT still significantly contributed to the accurate staging and management of our breast cancer patients, starting from the stage IIA. DOI: 10.17305/bjbms.2017.2179 PMCID: PMC5826677